Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II nivolumab trial in relapsed/refractory ALK-positive anaplastic large cell lymphoma
NL-OMON56001Phase 2Not yet recruiting
- Sponsor
- Gustave Roussy
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in anaplastic large cell lymphoma (ALCL) (2 cohorts), sponsored by Gustave Roussy. Primary endpoints: Best objective response rate within first 24 weeks and 3-year progression-free survival. Planned start May 2022; status: not yet recruiting.
02
Drugs
03
Conditions
anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NL-OMON56001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56001.